# Apixaban

## ELIQUIS 5mg

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | OELI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 適應症     | Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), w/ >=1 risk factors [eg, prior stroke or transient ischaemic attack, age >=75 yr, HTN, DM, symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.                                                                                                                                                                                                                                                                                                                                                                     |
| 用法用量   | Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years, body weight =<60 kg, or serum creatinine >=1.5 mg/dL, then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT                                                                                                                                                                                                                                                                                                                                                                                                           |
| 肝功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 腎功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 禁忌       | Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg, current or recent GI ulceration, presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury, brain/spinal/ophth surgery, intracranial haemorrhage; known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg, unfractionated heparin (UFH), low molecular wt heparins, heparin derivatives, oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter. |
| 副作用     | Epistaxis, anaemia, nausea, contusion, haematuria, haematoma, vag & urethral haemorrhage; eye, GI & rectal haemorrhage; gingival bleeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 孕期建議   | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 哺乳期建議 | No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Eliquis 2.5mg film-coated

##### 臨採

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | OELI2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 適應症     | Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), w/ >=1 risk factors [eg, prior stroke or transient ischaemic attack, age >=75 yr, HTN, DM, symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.                                                                                                                                                                                                                                                                                                                                                                     |
| 用法用量   | Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years, body weight =<60 kg, or serum creatinine >=1.5 mg/dL, then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT                                                                                                                                                                                                                                                                                                                                                                                                           |
| 肝功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 腎功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 禁忌       | Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg, current or recent GI ulceration, presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury, brain/spinal/ophth surgery, intracranial haemorrhage; known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg, unfractionated heparin (UFH), low molecular wt heparins, heparin derivatives, oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter. |
| 副作用     | Epistaxis, anaemia, nausea, contusion, haematuria, haematoma, vag & urethral haemorrhage; eye, GI & rectal haemorrhage; gingival bleeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 孕期建議   | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

